What GLP-1s Are
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of drugs that mimic a natural gut hormone. They slow stomach emptying, increase insulin release, decrease glucagon, and signal fullness to the brain. Net effect: lower glucose + less appetite + significant weight loss.
Brand names you'll recognise:
- Semaglutide — Ozempic (diabetes), Wegovy (weight), Rybelsus (oral)
- Tirzepatide — Mounjaro (diabetes), Zepbound (weight) — actually GLP-1 + GIP agonist, even more potent
- Liraglutide — Victoza (diabetes), Saxenda (weight)
- Dulaglutide — Trulicity (diabetes)
The Evidence: Real and Impressive
For type 2 diabetes
- A1c reduction: 1.0–1.8% (semaglutide), 1.5–2.2% (tirzepatide) — among strongest of any drug class
- Weight loss: 5–12% (semaglutide), 15–22% (tirzepatide) over 72 weeks
- Cardiovascular: 14–26% reduction in major adverse cardiovascular events (SUSTAIN-6, PIONEER-6)
- Kidney: semaglutide shown to slow kidney disease progression (FLOW trial, 2024)
- Mortality: significant reduction in all-cause mortality across large trials
For obesity without diabetes
- Weight loss: 15–17% at 68 weeks (STEP-1 trial with semaglutide 2.4mg)
- Tirzepatide (SURMOUNT-1): average 22% body weight loss at 72 weeks — historic for a non-surgical intervention
- Cardiovascular protection extending to non-diabetic obese patients
The Real Risks
1. Gastrointestinal (common)
60–70% of users experience nausea, 30–40% vomiting or diarrhoea, especially during the 4–8 week titration period. Usually manageable. Rarely severe enough to discontinue.
2. Gastroparesis (uncommon but serious)
Severe delayed stomach emptying. Can cause food retention, vomiting of undigested food, significant pain. Prevalence estimated 0.5–5% of long-term users, higher in those with existing GI disorders. Often persists even after discontinuation in some patients.
3. Pancreatitis (rare)
Risk elevated modestly — 1.2× baseline rate. Not common but real. Severe abdominal pain radiating to back is a warning sign requiring immediate attention.
4. Thyroid C-cell tumours (animal data; human unclear)
Seen in rats. Not clearly observed in humans. Contraindicated if personal or family history of medullary thyroid cancer or MEN 2.
5. Gallbladder disease
Rapid weight loss from any cause increases gallstone risk. GLP-1 users have 1.4–1.8× risk of gallstones. Symptoms (right upper abdominal pain after fatty meals) should not be ignored.
6. Muscle mass loss
Weight loss from GLP-1s is a mix of fat AND muscle. Without resistance training and adequate protein, 20–30% of weight lost may be muscle — bad for long-term metabolic health. This is a major under-discussed concern.
7. Bone density
Emerging concern with rapid weight loss and reduced food intake. Monitor especially in post-menopausal women.
8. Rebound weight gain
When GLP-1s are discontinued, 2/3 of lost weight typically returns within a year. Many patients treat this as a lifelong drug — which raises cost and long-term safety questions not yet answered.
9. Compounded/unregulated versions
'Compounded semaglutide' from wellness clinics often varies in purity and potency. Several US state boards have issued warnings. In India, unregulated imports of GLP-1s have caused severe adverse events. Always use branded, regulated medication.
Cost Reality
- USA: Ozempic $900–1200/month without insurance; Mounjaro similar
- Europe: €200–400/month out-of-pocket
- India: Ozempic recently launched at Rs. 14,000/month (as of 2026); Rybelsus (oral) ~Rs. 1,800/month for diabetics
Long-term cost is a real barrier. Generic versions expected around 2032.
Who Should Actually Take Them
Strong candidates
- Type 2 diabetes with A1c >7.5% despite metformin
- Existing cardiovascular disease (massive mortality benefit)
- Obesity (BMI >30) with metabolic complications
- Patients who've failed lifestyle intervention for 6+ months
Weaker candidates / caution
- Mild prediabetes (lifestyle usually works, drug overkill)
- Eating disorder history (GLP-1s can worsen)
- GI disorders (gastroparesis, IBD)
- Pregnancy planning (stop 2 months before)
- Personal/family history of medullary thyroid cancer
The Off-Label Wellness Use
Many non-diabetics seek GLP-1s for weight loss or anti-aging. Evidence for longevity benefit is very early. Evidence for weight loss is strong. But long-term use in metabolically healthy people has unknown consequences — the trials are only 68–104 weeks. Lifelong use has no data.
How to Stack GLP-1s Properly
- Pair with 1.6–2.0 g protein per kg bodyweight daily to protect muscle
- Add resistance training 2–3×/week — non-negotiable for muscle preservation
- Adequate fibre (25–35g/day) to counter constipation
- Hydration (GLP-1s blunt thirst)
- Multi-vitamin — reduced food intake risks micronutrient gaps
- Regular labs: liver, kidney, lipids, B12 every 6 months
- CGM if diabetic to adjust other medications (often can reduce/stop metformin, sulfonylureas)
Exit Strategy (Under-Discussed)
What happens when you stop? Most patients regain weight. Some have persistent GI changes. Some see diabetes return. Strategy:
- Don't stop cold turkey — taper with doctor
- Have lifestyle + behavior changes firmly in place before stopping
- Consider maintenance at lower dose rather than discontinuation
The Bigger Picture
GLP-1s are legitimate breakthroughs. The cardiovascular mortality data is historic. For the right patient — obese with T2D and existing heart disease — these drugs extend life measurably.
For the wrong patient — mildly overweight person without metabolic disease seeking cosmetic benefit — they're expensive, may cause gastroparesis, cause muscle loss, and have unknown long-term safety.
Our 365-day Diabetes Programme includes GLP-1 management when appropriate — endocrinologist-led titration, CGM-guided dose adjustment, nutrition support to preserve muscle, and a concrete plan for long-term use or eventual off-ramp. Without that framework, GLP-1s become an expensive bandage rather than a genuine solution.